CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
predicted neoantigen load. Prevalence estimates of MMR deficiency across solid tumor types range from 1% to 20% depending on the type of ma ...
Phase 2
Baltimore, Maryland, United States
Asymptomatic patients with metastatic castrate resistant prostate cancer (mCRPC) without pain due to prostate cancer...
Phase 2
Baltimore, Maryland, United States
The purpose of this study is to evaluate the effectiveness of CAN-2409 immunotherapy in patients undergoing active surveillance for localized prostate...
Phase 2
Bethesda, Maryland, United States and 22 other locations
This was a randomized study to evaluate the risk of major adverse cardiovascular events (MACE) for relugolix compared with leuprolide acetate. Enroll...
Phase 3
Washington, District of Columbia, United States and 107 other locations
The purpose of this study is to learn whether PYLARIFY PET imaging (study scan) can safely and accurately detect the presence or absence of prostate...
Phase 4
Baltimore, Maryland, United States and 9 other locations
Prostate cancer is usually treated by reducing the amount of testosterone in the body. PRL-02 depot is a potential treatment for me ...
Phase 1
Towson, Maryland, United States and 13 other locations
A Phase 1/2 study to evaluate the safety and efficacy of ARV-766 given by mouth alone or in combination with abiraterone in men with metastatic prostate...
Phase 1, Phase 2
Washington, District of Columbia, United States and 22 other locations
inhibitor, in Veterans with metastatic castration-resistant prostate cancer (mCRPC) characterized by either mismatch repair deficie...
Phase 2
Washington, District of Columbia, United States and 11 other locations
This study evaluates the efficacy, anti-tumor effect, and immunogenicity of neoadjuvant enoblituzumab given before radical prostatectomy. Pa...
Phase 2
Baltimore, Maryland, United States
radiation therapy for patients with intermediate-high risk localized prostate cancer. ProstAtak kills tumor cells and stim...
Phase 3
Washington, District of Columbia, United States and 72 other locations
Clinical trials
Research sites
Resources
Legal